porcine IFN-αm protein, its preparation method and application
By performing site-directed mutagenesis on porcine IFN-α protein and expressing it in Bacillus subtilis, the problems of low antiviral activity and complex preparation of existing porcine recombinant interferon were solved, enabling the industrial production of porcine IFN-αm protein at high efficiency and low cost.
Patent Information
- Application Number
- CN202611058001.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-16
- Publication Date
- 2026-11-17
AI Technical Summary
Existing porcine recombinant interferon has low antiviral activity and its preparation methods are complex and costly, making it difficult to meet the needs of industrial production.
By site-directed mutagenesis of porcine IFN-α protein, porcine IFN-αm protein was constructed and expressed in Bacillus subtilis. Soluble expression was achieved by utilizing the secretory capacity of Bacillus subtilis, thereby reducing production costs and improving antiviral activity.
Soluble expression of porcine IFN-αm protein in Bacillus subtilis was achieved, with a 10-fold increase in antiviral activity, reduced production costs, and suitability for industrial production.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to porcine IFN-αm protein, its preparation method, and its applications. Background Technology
[0002] The production of recombinant proteins is a fundamental task in modern biomanufacturing, and the expression of recombinant proteins in microbial strains is an important aspect of modern biotechnology. In recent years, the expression of heterologous proteins within host cells has been widely recognized and applied, and the scientific and industrial communities have continuously explored the use of bacteria with secretory capabilities for protein expression and production. By using these secretory host cells, the synthesized target protein can be directly secreted and accumulated in the extracellular culture medium, thus ensuring the cost-effectiveness and efficiency of downstream protein purification processes. Simultaneously, secretory expression can prevent excessive accumulation of heterologous proteins within host cells, as protein accumulation in host bacteria often leads to cytotoxicity and protein misfolding. Bacillus subtilis is the most important Gram-positive host bacterium, and approximately 60% of recombinant proteins in industry are expressed and produced using this bacterium. As an excellent microbial factory, Bacillus subtilis can produce and secrete various pharmaceutical proteins and enzymes, and due to its strong protein secretion capacity, its yield can be quantitatively controlled within a certain range. Furthermore, this bacterium has the advantages of being recognized as biosafety-assured (GRAS), having no biased codons, well-defined biochemical and physiological characteristics, strong genetic manipulability, and being conducive to downstream protein purification, thus making it suitable for large-scale industrial production of recombinant proteins.
[0003] Interferons (IFNs) are a family of cytokines that evolved in vertebrates and play important roles in the body, including antiviral, antitumor, and immunomodulatory functions. Based on their molecular characteristics, receptor interactions, and immune signaling pathways, interferons can be classified into three types: type I, type II, and type III. Each subtype of type I and type III contains multiple genotypes. Type I interferons include IFN-α, IFN-αω, IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-τ, IFN-ω, and IFN-ζ, and this subtype plays a crucial role in the body's antiviral immunity. Studies have reported that porcine IFN-α can inhibit the replication of various viruses and has shown some therapeutic effect on various viral infectious diseases in pigs in clinical practice. However, the existing porcine recombinant interferon has relatively low antiviral activity. Furthermore, current porcine recombinant interferon is produced industrially using eukaryotic (yeast, mammalian cells, etc.) and prokaryotic expression systems (E. coli). E. coli is the preferred industrial platform for recombinant interferon due to its low cost and high yield; however, its products often exist in inclusion body form, requiring cumbersome protein refolding to restore its activity, increasing production costs and severely affecting the efficacy of the protein drug. Moreover, E. coli endotoxin residue is the most critical quality control challenge in drug production, increasing the complexity and cost of the purification process. Therefore, there is an urgent need to research a porcine recombinant interferon with high antiviral activity, a simple preparation method, and low cost. Summary of the Invention
[0004] In view of the problems and shortcomings of the existing technology, the purpose of this invention is to provide porcine IFN-αm protein, its preparation method and application.
[0005] To achieve the objectives of this invention, the technical solution adopted is as follows: The first aspect of this invention provides a porcine IFN-αm protein, said porcine IFN-αm protein being a protein as shown in A1), A2), or A3) below: A1) A protein with the amino acid sequence shown in SEQ ID NO.1; A2) Proteins with the same function obtained by substituting and / or deleting and / or adding one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1; A3) Proteins that have 85% or more similarity to the amino acid sequence shown in SEQ ID NO.1 and have the same function; The specific amino acid sequence of SEQ ID NO.1 is as follows: MAPTSAFFTALVLLSCNAICSLGCDLPQTHSLAHTRALRLLAQMRRISPFSCLDHRDFGFPQEALGGRQKQKAQAMALVHEMLQQTFQLFSTEGSAAAWDESLLHQFCTGLDQQLRDLEACVMQEVGLEGTPELEEDSILAVRKYFHRLTLYLQEKSYSPCAWEIVRAEVMRAFSSSRNL.
[0006] A second aspect of the present invention provides a biomaterial related to the porcine IFN-αm protein of claim 1, which is any of the following: B1) A nucleic acid molecule encoding the porcine IFN-αm protein described in the first aspect above; B2), an expression cassette containing the nucleic acid molecule described in B1); B3) A recombinant vector containing the nucleic acid molecule described in B1), or a recombinant vector containing the expression cassette described in B2); B4) Recombinant microorganisms containing the nucleic acid molecules described in B1), or recombinant microorganisms containing the expression cassette described in B2), or recombinant microorganisms containing the recombinant vector described in B3).
[0007] Based on the above-mentioned biological material, preferably, the nucleotide sequence of the nucleic acid molecule described in B1) is as shown in SEQ ID NO.2. The nucleotide sequence shown in SEQ ID NO.2 is as follows: .
[0008] The third aspect of this invention provides the use of the porcine IFN-αm protein described in the first aspect or the biomaterial described in the second aspect in any of the following: C1) Use in the preparation of medicaments for the prevention, relief and / or treatment of viral infections; C2) Application in the preparation of immunomodulators; C3) Application in the preparation of vaccine adjuvants; C4) Application in the preparation of feed additives that promote pig growth.
[0009] According to the above application, preferably, the virus is at least one of pseudorabies virus, vesicular stomatitis virus, anti-swine reproductive and respiratory syndrome virus, foot-and-mouth disease virus, porcine epidemic diarrhea virus, porcine transmissible gastroenteritis virus, African swine fever virus, and swine influenza virus.
[0010] A fourth aspect of the present invention provides a medicament comprising an active ingredient, wherein the active ingredient is the porcine IFN-αm protein described in the first aspect or the biological material described in the second aspect. Preferably, the active ingredient is the porcine IFN-αm protein described in the first aspect, or the nucleic acid molecule described in B1) of the second aspect, or the expression cassette described in B2) of the second aspect, or the recombinant vector described in B3) of the second aspect.
[0011] According to the above-mentioned drug, preferably, the drug further contains a pharmaceutically acceptable carrier and / or excipients.
[0012] The fifth aspect of the present invention provides a feed additive containing the porcine IFN-αm protein described in the first aspect above.
[0013] A sixth aspect of the present invention provides a method for preparing the porcine IFN-αm protein described in the first aspect above, the method comprising the following steps: (1) Site-directed mutations were performed on amino acids 69, 71, and 134 of the amino acid sequence of wild-type pig IFN-α protein to obtain the amino acid sequence of pig IFN-αm protein; (2) Construct an expression vector containing a nucleotide sequence encoding the porcine IFN-αm protein; (3) The expression vector is transformed into host cells to obtain recombinant engineered bacteria; (4) The recombinant engineered bacteria were cultured, induced to express, and isolated and purified to obtain porcine IFN-αm protein.
[0014] According to the above preparation method, preferably, the host in step (2) is Bacillus subtilis.
[0015] According to the above preparation method, preferably, in step (3), the induction expression is induced by maltose.
[0016] Compared with the prior art, the positive and beneficial effects achieved by the present invention are as follows: (1) This invention constructs porcine IFN-αm protein by site-directed mutagenesis of the amino acid sequence of wild-type porcine IFN-α protein. The specific mutation sites and functional analysis are as follows: The asparagine (N) at position 69 of the amino acid sequence of wild-type porcine IFN-α protein is mutated to arginine (R). The 69th amino acid is located on the surface of the interferon molecule. The introduction of arginine can increase the local positive charge density, strengthen the electrostatic attraction between interferon and the negatively charged amino acid clusters in the extracellular region of the receptor (IFNAR1 / IFNAR2), thereby increasing the binding affinity and enhancing the downstream JAK-STAT signaling. The activation efficiency of the pathway was improved by mutating valine (V) at position 71 of the wild-type porcine IFN-α protein amino acid sequence to lysine (K). The long side chain of lysine can form a salt bridge with surrounding glutamic acid (E) or aspartic acid (D), which helps stabilize the local conformation of the protein and enhance its antiviral activity. Simultaneously, mutating leucine (L) at position 134 of the wild-type porcine IFN-α protein amino acid sequence to glutamic acid (E), and converting the hydrophobic leucine to hydrophilic glutamic acid, disrupts the hydrophobic core in this region, increases the hydration layer on the protein surface, reduces protein aggregation, and thus promotes its soluble expression in Bacillus subtilis. Therefore, this invention achieves the first soluble expression of porcine IFN-αm protein in Bacillus subtilis.
[0017] (2) This invention utilizes the porcine IFN-αm protein encoding gene poIFN-αm pMATE- was successfully constructed poIFN Expressive vehicle poIFN-αm The gene was successfully expressed in soluble form in Bacillus subtilis, and the purified protein achieved a purity of over 99%, exhibiting good reactivity. Experimental results showed that the antiviral titer of the recombinant porcine IFN-αm protein was 1.12 × 10⁻⁶. 7 U•mg -1 1 ng·mL -1 The recombinant porcine IFN-αm protein significantly inhibited PRV replication in cells, and its antiviral activity was superior to that of poIFN-α17 protein expressed in *E. coli*. Compared with poIFN-α17 protein, the purified porcine IFN-αm protein showed an approximately 10-fold increase in antiviral activity. Furthermore, mouse challenge protection experiments showed that porcine IFN-αm protein effectively inhibited PRV replication in vivo, significantly reduced the mortality rate of PRV-infected mice, and induced significantly higher levels of upregulation of cellular ISGs than poIFN-α17 protein, demonstrating that poIFN-αm possesses antiviral activity in vivo. Moreover, porcine IFN-αm exhibited no significant cytotoxicity or side effects in vivo or in vitro. Therefore, the porcine IFN-αm protein constructed in this invention possesses excellent antiviral activity and low toxicity.
[0018] (3) After treating PK-15 cells with porcine IFN-αm protein, the expression levels of IL-6, IFIT1, GBP1, SLA-DQB1, IRF1, and STAT2 genes were significantly upregulated, and their upregulated levels were significantly higher than those of cells treated with poIFN-α17 protein. This demonstrates that the protein can better induce the expression of key downstream antiviral proteins (such as IFIT1 and GBP1) and activate the body's antiviral response. At the same time, the upregulated expression of inflammatory response factors (IL-6), key genes of porcine leukocyte antigen complex (SLA-DQB1), transcription factors (IRF1), etc., indicates that porcine IFN-αm protein can regulate the body's inflammatory response and enhance acquired immunity, thereby enabling the body to comprehensively cope with the infection and invasion of pathogens.
[0019] (4) In summary, the porcine IFN-αm protein constructed by site-directed mutagenesis of porcine IFN-α interferon can be expressed in soluble form in Bacillus subtilis. The porcine IFN-αm protein has strong antiviral activity against PRV in vivo and in vitro, and can better induce the transcriptional expression of ISGs. The expression of porcine IFN-αm protein in Bacillus subtilis improves its antiviral activity, reduces production costs, and is more suitable for the industrial production of IFN, providing an efficient and safe expression platform for the development of antiviral agents for pigs. Attached Figure Description
[0020] Figure 1 For recombinant plasmid pMATE- poIFN The results of Nde I and Nhe I restriction enzyme digestion identification; where M is DL5000 DNA Marker, and 1 and 2 are both recombinant plasmids pMATE- poIFN 3 is the double enzyme digestion product; 3 is the buffer control; Figure 2 Figure 1 shows the SDS-PAGE electrophoresis results for identifying the expression of poIFN-αm protein in Bacillus subtilis; where M is the protein marker; 1 is the precipitate after lysis of blank Bacillus subtilis; 2 is the supernatant after lysis of blank Bacillus subtilis; 3 is the supernatant of induced culture of blank Bacillus subtilis; 4 is the precipitate after lysis of poIFN-αm expressing bacteria; 5 is the supernatant after lysis of poIFN-αm expressing bacteria; and 6 is the supernatant of induced culture of poIFN-αm expressing bacteria. Figure 3 The results of SDS-PAGE electrophoresis of the purified protein after purification using a HISTRAP HP protein affinity chromatography column are shown; where M is the protein marker and 1 is the purified protein. Figure 4The results of SDS-PAGE electrophoresis for the purified poIFN-αm protein product are shown; where M is the protein marker; 1 is the purified poIFN-αm protein product; and 2 is the buffer control. Figure 5 The results of Western blot analysis to identify the reactivity of poIFN-αm protein are as follows: 1 represents the poIFN-αm protein expressed by the poIFN-αm expressing bacteria; 2 represents the control strain of blank Bacillus subtilis (Bacillus subtilis strain not transformed with recombinant plasmid pMATE-poIFN). Figure 6 The results of the poIFN-αm protein cytotoxicity assay; Figure 7 PRV TCID in cell supernatant after treatment with poIFN-αm protein 50 Test results; Figure 8 10 ng·mL -1 IFA assay results of the inhibitory effect of poIFN-αm protein treatment on PRV; Figure 9 The results show the survival rate of mice. Figure 10 The results of detecting PRV viral load in organ tissues of mice in each group using quantitative real-time PCR method; Figure 11 This is the result of quantitative real-time PCR detection of the expression levels of intracellular IL-6, IFIT1, GBP1, SLA-DQB1, IRF1, and STAT2 genes; MOCK represents the blank control group. Detailed Implementation
[0021] To enable those skilled in the art to better understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below with reference to specific embodiments.
[0022] The following detailed description is exemplary and intended to provide further illustration of the invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0023] Unless otherwise specified, the test methods in the following examples all employ conventional techniques in this technical field or follow the conditions recommended by the manufacturer; reagents or instruments whose manufacturers are not specified are all commercially available conventional products.
[0024] The main materials involved in the following examples are as follows: DH5α competent cells were purchased from Dalian Takara Biotechnology Co., Ltd.; Bacillus subtilis expression vector and Bacillus subtilis competent cells were purchased from Tianjin Chunyao Biotechnology Co., Ltd.; PK15 cells were purchased from the Cell Bank of Wuhan University; PRV NY strain was isolated and kindly provided by the Animal Immunology Laboratory of Henan Agricultural University; BALB / c mice weighing 20 g and aged 5-7 weeks were purchased from Henan Skebest Biotechnology Co., Ltd.
[0025] The main reagents involved in the following examples are as follows: T4 ligase and agarose gel purification and recovery kit were purchased from New England Biolabs (NEB); Gibico fetal bovine serum was purchased from Thermo Fisher Scientific, Inc.; ECL chemiluminescence detection kit and high-glucose DMEM cell culture medium were purchased from Beijing Solarbio Science & Technology Co., Ltd.; cell RNA extraction kit and plasmid extraction kit were purchased from Omega Bio-Tek. Nde I and Nhe I restriction endonucleases were purchased from Dalian Takara Biotechnology Co., Ltd.; HISTRAP HP and HiLoad 16 / 600 Superdex protein purification columns were purchased from Cytiva Biotechnology Co., Ltd.; RNA reverse transcription kit and real-time PCR kit were purchased from Nanjing Novizan Biotechnology Co., Ltd.; CellTiter 96® AQueous One Solution Cell Proliferation Assay cytotoxicity assay kit was purchased from Promega Biotechnology Co., Ltd.; IFN-α antibody was purchased from Wuhan Yunclone Technology Co., Ltd.; and poIFN-α17 recombinant interferon protein was prepared in this experiment.
[0026] Example 1: Preparation of IFN-αm protein (poIFN-αm protein) 1. Analysis, optimization, and mutation of interferon amino acid sequences The nucleotide and amino acid sequences and structures of 44 subtypes of porcine interferon proteins (as shown in Table 1) were compared, analyzed, and predicted using AlphaFlod2 software. Based on the comparison, analysis, and structure prediction results, site-directed mutagenesis was performed on the amino acid sequence of wild-type porcine IFN-α protein to enhance protein solubility and antiviral activity. Specifically, the following site-directed mutagenesis was performed: asparagine (N) at position 69 of the wild-type porcine IFN-α protein amino acid sequence was mutated to arginine (R), valine (V) at position 71 was mutated to lysine (K), and leucine (L) at position 134 was mutated to glutamic acid (E). The resulting porcine IFN-αm protein (poIFN-αm protein) has the following amino acid sequence: MAPTSAFFTALVLLSCNAICSLGCDLPQTHSLAHTRALRLLAQMRRISPFSCLDHRDFGFPQEALGGRQKQKAQAMALVHEMLQQTFQLFSTEGSAAAWDESLLHQFCTGLDQQLRDLEACVMQEVGLEGTPELEEDSILAVRKYFHRLTLYLQEKSYSPCAWEIVRAEVMRAFSSSRNL (SEQ ID NO. 1).
[0027]
[0028] 2. Construction of recombinant plasmid pMATE-poIFN In the gene encoding the poIFN-αm protein— poIFN-αm Adding to both ends of the gene sequence Nde I and Nhe The I restriction enzyme site was sent to Zhejiang Shangya Biotechnology Co., Ltd. for synthesis, resulting in... poIFN-αm Gene fragments. The synthesized... poIFN-αm The gene fragment and the Bacillus subtilis expression vector pMATE AP (Chunyao MATE Bacillus subtilis expression system full plasmid kit 1.0, Tianjin Chunyao Biotechnology, CTBT10501) were both used. Nde I and Nhe Restriction endonuclease I was used for digestion, and the digestion products were subjected to agarose gel electrophoresis. The digested target nucleic acid fragment was then purified and recovered. The recovered product was ligated using T4 ligase at a 1:3 ratio and transformed into DH5α competent cells. Positive clones were selected, and plasmids were extracted. The extracted positive plasmids were digested with Nde I and Nhe I enzymes, and the digestion products were detected by agarose gel electrophoresis. Simultaneously, the extracted plasmids were sent to Zhejiang Shangzhiya Biotechnology Co., Ltd. for sequencing verification. The constructed plasmid with correct sequencing was named pMATE- poIFN .
[0029] The agarose gel electrophoresis results of the plasmid enzyme digestion products are as follows: Figure 1 As shown.
[0030] Depend on Figure 1 It can be seen that the recombinant plasmid pMATE- poIFN Specific target bands were observed at positions 7571 and 490 bp, consistent with the expected size, indicating that the recombinant plasmid pMATE- poIFN Successfully built.
[0031] 3. Transformation of Bacillus subtilis strain with recombinant plasmid pMATE-poIFN and induction of expression According to the kit instructions (Chunyao MATE Substance Expression System Full Plasmid Kit 1.0, Tianjin Chunyao Biotechnology, CTBT10501), the recombinant positive plasmid pMATE- poIFN Transform Bacillus subtilis competent cells, plate them on LB agar plates containing kanamycin, incubate overnight, pick single clones, and identify positive clones by colony-linked PCR. Add pMATE- poIFN Bacillus subtilis expressing the positive plasmid (denoted as poIFN-αm) was transfected with 5 mL of Kan resistance (50 μg·mL⁻¹). -1 LB liquid medium, incubated overnight at 37°C and 220 rpm. The next day, the activated bacterial culture was transferred to 2×SR medium (yeast extract 50 g / L, tryptone 30 g / L, K2HPO4 6 g / L), the initial bacterial culture... OD 600 Incubate at 0.1-0.2°C for 37°C at 220 rpm until the bacterial culture is complete. OD 600 The protein expression level was increased to 0.6-0.8. Maltose was then added to the culture medium at a final concentration of 3% for induction. The induction culture conditions were: 37℃, 220 rpm for 16 h. After the induction culture, the fermentation broth was centrifuged at 8000 rpm for 10 min, and the extracellular supernatant and bacterial cells were collected separately. The bacterial cells were subjected to ultrasonic lysis, followed by centrifugation, and the lysis supernatant and lysis precipitate were collected separately. The extracellular supernatant (denoted as poIFN-αm expression bacterial induction culture supernatant), the lysis supernatant (denoted as poIFN-αm expression bacterial lysis supernatant), and the lysis precipitate (poIFN-αm expression bacterial lysis precipitate) were then subjected to SDS-PAGE electrophoresis to detect protein expression. To provide a comparison, a control group of Bacillus subtilis without transformation to the recombinant plasmid pMATE-poIFN was set up. That is, Bacillus subtilis without transformation to the recombinant plasmid pMATE-poIFN (referred to as blank Bacillus subtilis) was cultured and induced to express under the same culture conditions. After induction, the fermentation broth was centrifuged at 8000 rpm for 10 min. After centrifugation, the supernatant of the induced culture of blank Bacillus subtilis and the blank Bacillus subtilis cells were collected. The blank Bacillus subtilis cells were subjected to ultrasonic lysis. The supernatant after lysis (referred to as the supernatant after lysis of blank Bacillus subtilis) and the precipitate after lysis (referred to as the precipitate after lysis of blank Bacillus subtilis) were collected separately. SDS-PAGE electrophoresis was performed on the supernatant of the induced culture of blank Bacillus subtilis, the supernatant after lysis of blank Bacillus subtilis, and the precipitate after lysis of blank Bacillus subtilis.
[0032] SDS-PAGE electrophoresis results are as follows: Figure 2 As shown. By Figure 2It was observed that a specific protein band around 19 kDa was present in the supernatant after lysis of poIFN-αm-expressing bacteria, while this specific band was not found in the lysate of poIFN-αm-expressing bacteria, the supernatant of poIFN-αm-expressing bacteria induction culture, the lysate of blank Bacillus subtilis, the supernatant of blank Bacillus subtilis lysate, or the supernatant of blank Bacillus subtilis induction culture. This indicates that poIFN-αm was successfully expressed in Bacillus subtilis.
[0033] 4. Preparation of IFN-αm protein The poIFN-αm expression bacteria constructed in step 3 above were transferred into 2×SR medium (yeast extract 50 g / L, tryptone 30 g / L, K2HPO4 6 g / L) and cultured at 37℃ and 220 rpm until the bacterial culture was complete. OD 600 After reaching a pH of 0.6-0.8, the bacterial cells were collected by centrifugation and then sonicated to disrupt the protein. The supernatant was collected. The collected supernatant was then purified using a HISTRAP HP protein affinity chromatography column on an AKATA protein purifier. The purified protein was analyzed by SDS-PAGE electrophoresis, and the results are shown below. Figure 3 As shown. Further purification of the protein was achieved using a HiLoad 16 / 600 Superdex 75 pg molecular sieve for desalting and purification. The effluent was collected to obtain the purified poIFN-αm protein product. The purified poIFN-αm protein product was subjected to SDS-PAGE electrophoresis to determine the purity of the poIFN-αm protein (results are shown in the figure). Figure 4 (as shown in the figure), and the concentration of poIFN-αm protein was determined using the BCA protein concentration assay kit, and then aliquoted and stored at -80 ℃ for later use.
[0034] Depend on Figure 3 It can be seen that after purifying the protein from the supernatant using a HISTRAP HP protein affinity chromatography column on an AKATA instrument, the purity of the poIFN-αm protein in the purified protein can reach over 90%. Figure 4 It can be seen that the purified poIFN-αm protein product obtained by purification treatment using HiLoad16 / 600 Superdex 75 pg molecular sieve can achieve a purity of over 99%.
[0035] 5. Western blot identification of the reactivity of poIFN-αm protein The reactivity of poIFN-αm protein was identified using Western blotting. The specific procedure was as follows: The purified poIFN-αm protein product prepared in step 4 was subjected to SDS-PAGE protein electrophoresis, then transferred to a cellulose acetate membrane. A 1:1000 dilution of mouse anti-porcine poIFN antibody was used as the primary antibody, and horseradish peroxidase-labeled goat anti-mouse antibody was used as the secondary antibody. Colorimetric detection was performed using an ECL chemiluminescence assay kit. The results are shown below. Figure 5 As shown.
[0036] Depend on Figure 5 As can be seen, the purified poIFN-αm protein product exhibits clear, specific bands at the expected molecular weight positions with a clean background and no obvious non-specific bands. This confirms that the poIFN-αm protein possesses good immunoreactivity and can be accurately recognized by specific antibodies. This result further validates the structural integrity and biological activity basis of the purified poIFN-αm protein product, indicating that the poIFN-αm protein obtained through the preparation process in step 4 above is not only highly pure but also retains its native antigenic epitopes, meeting the quality requirements for subsequent functional studies and application development.
[0037] Example 2: Determination of poIFN-αm protein cytotoxicity and antiviral titer 1. Detection of poIFN-αm protein cytotoxicity: PK-15 cells were seeded into 96-well cell culture plates. After the cells grew into a monolayer, they were cultured using 0.001–10 μg / mL... -1 Purified poIFN-αm protein (prepared according to the method described in step 4 of Example 1) was used to treat PK-15 cells, with three replicate wells for each dilution, and an untreated cell control (Mock). Cytotoxicity was then assessed at 48 h using the CellTiter 96® AQueous OneSolution Cell Proliferation Assay kit. The results are as follows: Figure 6 As shown.
[0038] Depend on Figure 6 It can be seen that the concentration of poIFN-αm protein in PK-15 cells is less than 10 μg·mL. -1 It has no obvious toxic effects on cells.
[0039] 2. Determination of the antiviral potency of poIFN-αm protein: PK-15 cells were seeded into 96-well cell culture plates, and four groups were prepared: poIFN-αm protein group, poIFN-αm protein + VSV group, VSV group, poIFN-α17 protein group, and poIFN-α17 protein + VSV group. The poIFN-αm protein + VSV group was treated as follows: after the cells grew into a monolayer, purified poIFN-αm protein (prepared according to the method described in step 4 of Example 1) was serially diluted 10-fold and added to the 96-well plate, resulting in 11 dilutions, with 4 replicates per dilution, and incubated for 24 h. Then, 1000 TCID⁻¹ was seeded into each well. 50 The vesicular stomatitis virus (VSV) was cultured for 24 h. The treatment of the poIFN-αm protein group was basically the same as that of the poIFN-αm protein + VSV group, except that VSV virus was not inoculated. The treatment method for the poIFN-α17 protein + VSV group was as follows: After the cells grew into a monolayer, the purified poIFN-α17 protein (poIFN-α17 protein was prepared according to the method described in the literature "Preparation of Highly Active Porcine Interferon α17m Based on Natural poIFN-α17 Mutation and Its In Vitro Antiviral Activity"; the specific literature information of "Preparation of Highly Active Porcine Interferon α17m Based on Natural poIFN-α17 Mutation and Its In Vitro Antiviral Activity" is as follows: Fang Jianyu, You Yi, Xi Yanyan, Zhang Qingxian, Mao Zhanzhan, Xu Bin, Lang Limin, Chen Hongying & Li Shaoyu (2024) Preparation of Highly Active Porcine Interferon α17m Based on Natural poIFN-α17 Mutation and Its In Vitro Antiviral Activity, Chinese Journal of Veterinary Medicine. 44, 921-927) was serially diluted 10-fold and added to a 96-well plate, with a total of 11 dilutions, 4 replicates per dilution, and incubated for 24 h; then 1000 μL of each culture well was seeded. TCID 50 VSV virus was cultured for 24 h. The treatment method for the poIFN-α17 protein group was basically the same as that for the poIFN-αm protein + VSV group, except that VSV virus was not inoculated. The treatment method for the VSV group was basically the same as that for the poIFN-αm protein + VSV group, except that the cells were not treated with poIFN-αm protein, but only inoculated with VSV virus. Then, the cells of each group were washed with physiological saline, and cell fixation and staining solution was added to the cell wells. The cells were incubated at room temperature for 1 h, the fixation and staining solution was discarded, and the cells were rinsed with tap water 3-5 times. 200 μL of 2-methoxyethanol was added to dissolve the staining solution. The cell culture plate readings were detected by spectrophotometer at 550 nm. The percentage of antiviral activity was calculated using the formula: Antiviral activity (%) = (D 550 +IFN -D 550 -IFN )×100 (D550 Mock -D 550 -IFN D 550 +IFN This indicates that cells were treated with gentian violet-stained IFN after VSV virus infection. OD Values (i.e., poIFN-αm protein + VSV group or poIFN-α17 protein + VSV group cells) OD Value); D 550 -IFN These represent untreated IFN cells stained with gentian violet after VSV virus infection. OD Value (i.e., D value of poIFN-αm proteome or poIFN-α17 protein cells); D 550 Mock Indicates VSV group cells OD value.
[0040] The highest dilution of the *E. coli*-expressed recombinant poIFN-α17 protein that inhibited half-cell cytopathic effects was 10. -5 and 10 -6 Between these values, one unit of interferon activity can be defined. The calculated antiviral titer of poIFN-αm protein against VSV is 1.12 × 10⁻⁶. 7 U·mg -1 The antiviral titer of poIFN-α17 protein against VSV was 2.32 × 10⁻⁶. 6 U·mg -1 (As shown in Table 2). This result indicates that, compared with the poIFN-α17 protein, the poIFN-αm protein has a more than 10-fold increased antiviral titer and can better inhibit VSV replication.
[0041]
[0042] Example 3: Assay of the activity of recombinant poIFN-αm protein against pseudorabies virus (PRV) 1. Assay of in vitro antiviral activity of poIFN-αm protein PK-15 cells were seeded into 24-well plates and cultured overnight to form a monolayer. Cells were then treated with different concentrations of poIFN-αm protein (prepared according to the method described in step 4 of Example 1) and poIFN-α17 protein (poIFN-α17 protein was prepared according to the method described in the literature "Preparation of Highly Active Porcine Interferon α17m Based on Natural poIFN-α17 Mutation and Its In Vitro Antiviral Activity"; the specific literature information for "Preparation of Highly Active Porcine Interferon α17m Based on Natural poIFN-α17 Mutation and Its In Vitro Antiviral Activity" is as follows: Fang Jianyu, You Yi, Xi Yanyan, Zhang Qingxian, Mao Zhanzhan, Xu Bin, Lang Limin, Chen Hongying & Li Shaoyu (2024) Preparation of Highly Active Porcine Interferon α17m Based on Natural poIFN-α17 Mutation and Its In Vitro Antiviral Activity, Chinese Journal of Veterinary Medicine. 44, 921-927). After 24 h, cells were seeded with 100 TCID⁻¹. 50 PRV virus; cells and cell supernatant were collected 24 h after inoculation, and the TCID of PRV in the cell supernatant was measured. 50 The collected cells were then subjected to indirect immunofluorescence assay (IFA) to observe the inhibitory effect of poIFN-αm protein on PRV virus. For comparison, a blank control group and a PRV virus control group were also set up. The blank control group was not treated with interferon and was not inoculated with PRV. The PRV virus control group was treated as follows: PK-15 cells were inoculated with PRV virus only, without treatment with poIFN-αm or poIFN-α17 protein.
[0043] Among them, the TCID of PRV in cell supernatant 50 Test results as follows Figure 7 As shown. 10 ng·mL -1 The IFA assay results of the inhibitory effect of poIFN-αm protein treatment on PRV virus are as follows: Figure 8 As shown.
[0044] Depend on Figure 7 It can be known that 1 ng·mL -1 poIFN-αm protein significantly inhibited PRV replication on cells, and its anti-PRV effect was significantly better than that of poIFN-α17 protein. Furthermore, at 1000 ng / mL... -1 poIFN-αm can completely block PRV replication.
[0045] Depend on Figure 8 It can be known that 10 ng·mL -1 The poIFN-αm protein showed significantly better anti-PRV effects than the poIFN-α17 protein expressed in E. coli on PK-15 cells.
[0046] 2. Determination of the antiviral activity of poIFN-αm protein in mice (1) Experimental method: Forty-five mice were randomly divided into three groups: a blank control group (n=15), a PRV challenge control group (n=15), and an interferon treatment group (n=15). Each mouse in the PRV challenge control group and the interferon treatment group was subcutaneously injected with 0.2 mL of 5×10⁻⁶ PRV solution. 4 PRV TCID 50 •mL -1 Virus solution was administered, while the blank control group was injected with an equal volume of DMEM medium containing 2% serum. At 12, 24, and 48 hours post-challenge, each mouse in the interferon treatment group received an intramuscular injection of 20 μg of poIFN-αm protein in its leg. The blank control and PRV challenge control groups received an equal volume of PBS solution. After interferon injection, the mice's appetite, mental state, and other clinical manifestations were observed daily. The number of deaths and survival rates were also calculated for each group. On day 5 post-challenge, five mice from each group were randomly selected for dissection, and brain and liver tissues were collected. Nucleic acid was extracted after grinding, and the PRV viral load in the organ tissues was detected using quantitative real-time PCR.
[0047] (2) Experimental results: 1) Statistics on clinical symptoms and survival rates of mice in each group after the study: After administration of the drug to the PRV-treated group, the clinical symptoms of the mice were observed daily. The results showed that in the PRV-treated control group, most mice exhibited symptoms such as rough fur, decreased appetite, and depression 3 days after the initial challenge, and scratched their mouth, nose, face, and back injection sites. In the interferon-treated group, the clinical symptoms were significantly reduced, with only a few mice showing mild symptoms. The number of deaths and survival rates were calculated for each group. The results showed that in the PRV-treated control group, 5 mice died on day 3 (survival rate 66.7%), 6 mice died on day 4 (survival rate 26.7%), 3 mice died on day 5 (survival rate 6.7%), and all mice died on day 6 (survival rate 0%). In the interferon-treated group, 3 mice died on day 4 (survival rate 80%), 2 mice died on day 5 (survival rate 66.7%), 1 mouse died on day 6 (survival rate 60.0%), and 1 mouse died on day 8 (survival rate 53.3%), with the remaining 8 mice surviving. All mice in the blank control group survived (e.g., ...). Figure 9 (As shown in the image). This result indicates that treatment with poIFN-αm protein significantly reduced the mortality rate in PRV-infected mice.
[0048] 2) Detection of viral load in mouse organs and tissues after challenge: The results of detecting PRV viral load in organ tissues of mice in each group using the real-time quantitative PCR method are as follows: Figure 10 As shown. By Figure 10The results showed that the viral load in the brain and liver tissues of mice in the interferon treatment group was significantly lower than that in the PRV challenge control group, while viral nucleic acid was not detected in mice in the blank control group. These results indicate that poIFN-αm can significantly inhibit PRV replication in the brain and liver tissues of mice.
[0049] The above results indicate that the poIFN-αm protein has antiviral activity (especially against PRV virus) in vivo.
[0050] Example 4: Study on the activating effect of poIFN-αm protein on downstream ISG genes of interferon 1. Design and synthesis of primers for real-time quantitative PCR Based on the IL-6, IFIT1, GBP1, SLA-DQB1, IRF1, and STAT2 gene sequences registered in GenBank, real-time quantitative PCR primers were designed using Primer 5.0 software (as shown in Table 2) and synthesized by Zhejiang Shangya Biotechnology Co., Ltd.
[0051]
[0052] 2. The activating effect of recombinant protein poIFN-αm on downstream ISG genes. PK-15 cells were seeded in 24-well cell culture plates at a density of 1 × 10⁶ cells per well. 5 After the cells have grown into a monolayer, use 1 μg·mL⁻¹ -1 Cells were treated with poIFN-αm or poIFN-α17 protein, with three replicates for each protein. A blank control group was also set up (cells were seeded in 24 wells only, without virus inoculation or interferon treatment). After 24 h, cells were collected, RNA was extracted, and then the expression levels of IL-6, IFIT1, GBP1, SLA-DQB1, IRF1, and STAT2 genes in cells were detected by real-time PCR using the PCR primers designed in step 1 above.
[0053] Data Analysis: GrapaPad Prism 9.0 software was used for data statistics, analysis, and graphing. P< 0.05 Significant differences are indicated by an asterisk (*). P< 0.01 The difference is highly significant and marked with "**". P<0.001 The difference is marked as "***" to indicate that it is extremely significant. P ≥ 0.05 This indicates that the difference is not significant, and is marked as "ns".
[0054] The results of detecting the expression levels of intracellular IL-6, IFIT1, GBP1, SLA-DQB1, IRF1, and STAT2 genes using quantitative real-time PCR are as follows: Figure 11 As shown.
[0055] Depend on Figure 11 The results showed that, compared with the blank control group, poIFN-αm protein effectively induced the upregulation of IL-6, IFIT1, GBP1, SLA-DQB1, IRF1, and STAT2 gene expression levels. Furthermore, poIFN-αm protein induced significantly higher expression levels of IL-6, IFIT1, GBP1, SLA-DQB1, IRF1, and STAT2 genes in PK-15 cells compared to poIFN-α17 protein. These results indicate that poIFN-αm protein can better induce the expression of key downstream antiviral proteins (such as IFIT1 and GBP1), activating the body's antiviral response. Simultaneously, it upregulated the expression of inflammatory response factors (IL-6), key genes of the porcine leukocyte antigen complex (SLA-DQB1), and transcription factors (IRF1), regulating the body's inflammatory response and enhancing acquired immunity, thereby enabling the body to comprehensively respond to pathogen infection and invasion.
[0056] Finally, it should be noted that the above embodiments are merely preferred embodiments of the present invention and are not intended to limit the present invention in any other way. Any person skilled in the art may use the above technical content as inspiration to make changes or modifications. These are equivalent embodiments with variations. However, any simple modifications, equivalent changes, and modifications made to the above embodiments based on the technical essence of the present invention without departing from the technical concept of the present invention still fall within the protection scope of the claims of the present invention.
Claims
1. A porcine IFN-αm protein, characterized in that, The porcine IFN-αm protein is the protein shown in A1), A2), or A3) below: A1) A protein with the amino acid sequence shown in SEQ ID NO.1; A2) Proteins with the same function obtained by substituting and / or deleting and / or adding one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1; A3) Proteins that have 85% or more similarity to the amino acid sequence shown in SEQ ID NO.1 and have the same function.
2. The biomaterial related to the porcine IFN-αm protein of claim 1 is any one of the following: B1) A nucleic acid molecule encoding the porcine IFN-αm protein of claim 1; B2), an expression cassette containing the nucleic acid molecule described in B1); B3) A recombinant vector containing the nucleic acid molecule described in B1), or a recombinant vector containing the expression cassette described in B2); B4) Recombinant microorganisms containing the nucleic acid molecules described in B1), or recombinant microorganisms containing the expression cassette described in B2), or recombinant microorganisms containing the recombinant vector described in B3).
3. The biomaterial of claim 2, wherein, B1) The nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO.
2.
4. The use of the porcine IFN-αm protein of claim 1 or the biomaterial of claim 2 or 3 in any of the following: C1) Use in the preparation of medicaments for the prevention, relief and / or treatment of viral infections; C2) Application in the preparation of immunomodulators; C3) Application in the preparation of vaccine adjuvants; C4) Application in the preparation of feed additives that promote pig growth.
5. Use according to claim 4, characterized in that, The virus is at least one of pseudorabies virus, vesicular stomatitis virus, anti-swine reproductive and respiratory syndrome virus, foot-and-mouth disease virus, porcine epidemic diarrhea virus, porcine transmissible gastroenteritis virus, African swine fever virus, and swine influenza virus.
6. A medicament, characterized by comprising: The drug contains an active ingredient, which is the porcine IFN-αm protein of claim 1 or the biological material of claim 2 or 3.
7. The medicament according to claim 6, characterized in that, The drug also contains pharmaceutically acceptable carriers and / or excipients.
8. A feed additive, characterized in that, The feed additive contains the porcine IFN-αm protein as described in claim 1.
9. A method for preparing the porcine IFN-αm protein according to claim 1, characterized in that, Includes the following steps: (1) Site-directed mutations were performed on amino acids 69, 71, and 134 of the amino acid sequence of wild-type pig IFN-α protein to obtain the amino acid sequence of pig IFN-αm protein; (2) Construct an expression vector containing a nucleotide sequence encoding the porcine IFN-αm protein; (3) The expression vector is transformed into host cells to obtain recombinant engineered bacteria; (4) The recombinant engineered bacteria were cultured, induced to express, and isolated and purified to obtain porcine IFN-αm protein.
10. The preparation method according to claim 9, characterized in that, The host mentioned in step (2) is Bacillus subtilis; in step (3), the induction expression is induced by maltose.
